Wellgistics Health Inc

This management proposal seeks shareholder approval to amend the Company’s Certificate of Incorporation to change the corporate name from Wellgistics Health, Inc. to DataMeds AI, Inc. Management presents the name change as aligning the corporate identity with the Company’s strategic focus on healthcare technology and pharmaceutical services—a rebranding intended to clarify market positioning and support future business development. The proposal is procedural in nature and does not alter corporate rights, outstanding securities, or stockholder economic interests; stock certificates remain valid and no certificate exchange is required solely because of the name change. Management argues the change will better communicate the Company’s technology-forward, patient-centric platform and may include a Nasdaq ticker change to “MEDS” if approved by Nasdaq. The Board unanimously recommends approval, emphasizing branding and strategic alignment as the primary rationale. For investors, the primary considerations are whether the rebranding will materially assist commercialization, partnership or capital-raising efforts and whether it raises any governance concerns (it does not). Because the change does not modify shareholder rights or capital structure, the material economic impact on holders is negligible, though there could be modest administrative costs. Given the Board’s unanimous support and the straightforward nature of the amendment, the proposal should be evaluated largely on the strategic merits of repositioning the corporate identity and expected operational benefits rather than shareholder dilution or governance change.

This management proposal asks shareholders to amend the Certificate of Incorporation to add authority for 1,000,000 shares of preferred stock, granting the Board broad discretion to create one or more series with varying rights and preferences. Management frames the change as a means to increase strategic and financing flexibility—allowing the Board to structure preferred issuances for future capital raises, strategic transactions, or other corporate purposes without returning to shareholders for each specific series. The company discloses potential anti‑takeover effects: blank‑check preferred can be used to dilute or frustrate activist or hostile bids by creating a class of shares with tailored voting or economic terms. The Board states it does not propose the amendment with the intent to entrench management, but notes that such outcomes could theoretically result, and discloses that approval is necessary to implement Proposal No. 4 (the Super‑Voting Preferred). For shareholders this proposal presents a trade‑off between management flexibility for legitimate corporate needs and the potential for future governance actions that may dilute common holders’ voting power or economic interest. The Board’s unanimous recommendation and articulation of business reasons (flexibility, ability to structure transactions) support approval, but investors should weigh that against the lack of specificity about potential future uses and the anti‑takeover risk. Given the broad discretion conferred, if approved investors and governance-focused stakeholders may want continued monitoring and potential limits on specific future issuances to protect minority holders.

This management proposal would materially expand the company’s equity incentive capacity by (1) changing the annual automatic increase to the plan’s share reserve from 3% to up to 20% of outstanding common stock (effective January 1, 2027) and (2) expressly reserving up to 6,000 shares of the newly created Series A Super‑Voting Preferred for issuance under the Incentive Plan. Management argues the amendments are required to attract, retain and motivate employees, directors and consultants as the company scales, and to provide multi‑year flexibility for equity compensation without repeated shareholder votes. The amendment substantially increases the maximum potential dilution that could be granted annually—raising governance concerns because the automatic increase scales with the share count and administrators retain discretion to set the actual increase each year. The Board emphasizes that awards will typically be subject to vesting and performance conditions and that the Administrator can choose a lesser increase or none in any year, which moderates immediate dilution risk but leaves significant discretion with management. Reserving super‑voting preferred shares under the plan ties compensation to a security that confers massive voting power per share, which raises potential entrenchment concerns because these awards would combine governance control (via voting power) with equity compensation incentives. The proposal intersects with Nasdaq rules and will require careful implementation and disclosure about recipients, transfer restrictions, vesting and sunset mechanisms to mitigate governance risk. For sophisticated investors, the balance is between the company’s need for competitive compensation tools and the governance risk from potential concentrated voting power and increased dilution; monitoring post‑approval grant practices and limits will be critical. The Board’s unanimous recommendation reflects the company’s stated growth and hiring needs, but shareholders should scrutinize the Administrator’s future use of the expanded authority.

This management proposal requests shareholder approval to create and issue a 6,000‑share series of Series A Super‑Voting Preferred Stock to certain directors and executive officers, each share carrying 10,000 votes—a structure designed to concentrate significant voting power in a small number of instruments. Management frames the instrument as a tool to provide voting stability and continuity for multi‑year strategic initiatives while minimizing economic dilution because the shares carry nominal liquidation and dividend rights and are non‑convertible. The company proposes transfer restrictions, sunset events tied to termination or transfer, and board‑approved redemption mechanisms to limit permanent entrenchment; however, even with such guardrails the voting concentration could materially alter corporate control dynamics. The issuance will implicate Nasdaq rules governing insider issuances and potential change‑of‑control determinations, prompting the company to seek stockholder approval under those listing rules. For shareholders the principal risk is governance—these shares can make it materially harder to change board composition or approve transactions opposed by holders of the super‑voting shares even if those holders have limited economic exposure. Management’s unanimous recommendation rests on asserted benefits to execution and continuity, but independent shareholders and governance-focused investors will weigh these benefits against the risk of concentrated voting control, especially given the small number of shares and the extreme votes-per‑share ratio. Post‑approval, investors should monitor exact allocations, transfer/vesting rules, and sunset mechanics to assess real‑world impact on control and potential mitigation of entrenchment concerns.